Supramaximal resection in IDH-mutant grade 2 gliomas is associated with improved survival outcomes, ref: Karschnia doi.org/10.1016/S1470-2045(25)00534-0/
Loss of global DNA hypermethylation is a significant prognostic factor in IDH-mutant and 1p/19q-codeleted oligodendrogliomas, ref: Hinz doi.org/10.1007/s00401-025-02963-7/
Proton beam therapy enhances patient-reported outcomes and neurocognitive functioning in IDH1-mutant diffuse gliomas, ref: Pelak doi.org/10.1016/j.ijrobp.2025.10.025/
Magnetic resonance spectroscopy reveals elevated cystathionine and 2-hydroxyglutarate levels in IDH-mutant gliomas, ref: Choi doi.org/10.1002/nbm.70181/
Combination of lenvatinib and PARP inhibitors shows promise in overcoming treatment resistance in IDH-mutant gliomas, ref: Yang doi.org/10.1002/advs.202503866/
Portable duplex digital PCR enables rapid detection of IDH mutations, enhancing diagnostic efficiency, ref: Jung doi.org/10.1016/j.bios.2025.118207/
MRI-derived features correlate with DNA methylation grades in IDH-mutant astrocytomas, facilitating non-invasive tumor classification, ref: Singh doi.org/10.1007/s00234-025-03766-z/